| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb351a5a4e03ee3773bd0df5dbae9ac3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-61 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 |
| filingDate |
2022-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5726631815a783747c5d43e82e297ffe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11c2e4c4296697450e6d08108ee76c63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8489f4f6083a9dab8043c4652b1064bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c8ff088c5126c26626a9e7069a0c39f |
| publicationDate |
2022-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-115089724-A |
| titleOfInvention |
A kind of preparation method and application of exosome-polymer hybrid nanoparticle for oral colon targeted drug delivery |
| abstract |
The invention discloses a preparation method and application of an exosome-polymer hybrid nanoparticle for oral colon targeted drug delivery, and belongs to the field of biomedicine. The preparation method of exosome-polymer hybrid nanoparticles for oral colon targeted drug delivery provided by the present invention is to firstly connect pterostilbene and chondroitin sulfate through oxalyl chloride to form an amphiphilic polymer Then, the fat-soluble pterostilbene was injected into the exosome membrane by ultrasonic crushing, and the chondroitin sulfate was covered on the surface of the exosome membrane to form exosome-polymer hybrid nanoparticles. Biocompatibility, can actively target to the surface of colonic macrophage CD44, in the case of a sharp increase in reactive oxygen species in inflammatory colon tissue, the oxalate bond in the exosome-polymer hybrid nanoparticle is destroyed and released Exosomes and pterostilbene are released, and then exert their anti-inflammatory and antioxidant effects, effectively promoting the regeneration and repair of tissues at the site of inflammation. |
| priorityDate |
2022-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |